The Patient Enrollment in FIRE2 – DIABETES Clinical Trial Completed

On July 16, 2011, MicroPort completed enrollment of 1000 patients in its FIRE2 – DIABETES (Efficacy and Safety of Firebird2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent in Treatment of Complex Coronary Lesions in Diabetes) clinical trial. Meanwhile, the clinical follow-up for 30 days, 6 months and a year respectively, are already underway according to schedule. FIRE2 – DIABETES is an international multi-center prospective clinical registry research which involved over 40 research centers all over the world. All of the implanted stents were Firebird2 cobalt-chromium alloyed sirolimus-eluting stents. The findings of the research will provide scientific basis for the efficacy and safety of the products in treatment of complex coronary lesions in diabetes.